Stockwinners Market Radar for October 21, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:29 EDT Annexon presents Phase 2 Vision Preservation data with ANX007 in dry AMD - The company states: "Annexon announced new findings from its Phase 2 ARCHER study for ANX007 in geographic atrophy due to dry age-related macular degeneration. ANX007 demonstrated enhanced protection of vision and greater preservation of central photoreceptor cells in a subpopulation of patients with less advanced disease as measured by the photoreceptor ellipsoid zone in the central fovea. The data were presented at the American Academy of Ophthalmology 2024 annual meeting. ANX007 is a first-in-kind, non-pegylated antigen-binding fragment designed to block C1q locally in the eye with an intravitreal formulation. As previously described, in the randomized Phase 2 ARCHER trial, ANX007 demonstrated a visual function benefit consistently across multiple measures that was both dose and time dependent. This includes significant broad-based protection of vision in standard and low light conditions and significant protection of photoreceptors in the fovea region critical for visual acuity. These Phase 2 data are further reinforced in a subpopulation of patients with less advanced disease defined by low light visual acuity less than 30 at baseline and in patients with more intact vision as defined by less than80% EZ loss."

20:13 EDT Cathie Wood's ARK Investment buys 103.2K shares of 3D Systems today

19:01 EDT Thoughtworks to partner with Swann to develop SwannShield - The company states: "Thoughtworks announces a pioneering collaboration with Swann to develop SwannShield(TM) - an innovative AI-powered home security voice assistant. A leading global provider of security monitoring, consumer electronics and security-centric solutions, Swann empowers people to protect and stay connected to their home or business no matter where life takes them."

18:28 EDT Point72 Asset Management reports 5.4% passive stake in Shoals Technologies - Point72 Asset Management disclosed a 5.4% stake in Shoals Technologies, which represents over 9.0M shares. The filing does not allow for activism. Shares are up 5% afterhours at $5.30.

17:42 EDT Insteel unit acquires welded wire reinforcement firm EWP for $70M - Insteel Industries announced earlier, that its wholly-owned subsidiary, Insteel Wire Products Company has acquired Engineered Wire Products or EWP for $70M in an asset transaction, subject to certain adjustments. The transaction was funded from cash on hand. EWP is a leading manufacturer of welded wire reinforcement products for use in nonresidential and residential construction. For the twelve months ended September 30 , EWP's sales were $93.3M. "We are pleased to complete the acquisition of EWP. This move will expand our geographic footprint and bolster our competitive position in the Midwest market," stated H.O. Woltz III, President and CEO of Insteel. "The acquisition of EWP will enhance our customer service capabilities and drive down operating costs through operational synergies."

17:33 EDT IBM introduces Granite 3.0 'high performing' AI Mmodels built for business - Earlier, at IBM's annual TechXchange event the company announced the release of its most advanced family of AI models to date, Granite 3.0. IBM's third-generation Granite flagship language models can outperform or match similarly sized models from leading model providers on many academic and industry benchmarks, showcasing strong performance, transparency and safety.Consistent with the company's commitment to open-source AI, the Granite models are released under the permissive Apache 2.0 license, making them unique in the combination of performance, flexibility and autonomy they provide to enterprise clients and the community at large.The new Granite 3.0 8B and 2B language models are designed as 'workhorse' models for enterprise AI, delivering strong performance for tasks such as Retrieval Augmented Geneneration RAG , classification, summarization, entity extraction, and tool use. These compact, versatile models are designed to be fine-tuned with enterprise data and seamlessly integrated across diverse business environments or workflows. While many large language models LLMs are trained on publicly available data, a vast majority of enterprise data remains untapped. By combining a small Granite model with enterprise data, especially using the revolutionary alignment technique InstructLab - introduced by IBM and RedHat in May - IBM believes businesses can achieve task-specific performance that rivals larger models at a fraction of the cost. The Granite 3.0 release reaffirms IBM's commitment to building transparency, safety, and trust in AI products. The Granite 3.0 technical report and responsible use guide provide a description of the datasets used to train these models, details of the filtering, cleansing, and curation steps applied, along with comprehensive results of model performance across major academic and enterprise benchmarks.

17:16 EDT Boeing awarded $277.05M Air Force contract - Boeing was awarded a $277.05M cost, cost-plus-fixed-fee contract for Starfire Electro-Optics, Laser Lab Advancement. This contract provides for the development of Electro-Optics and Directed Energy technologies, in support of the Air Force Research Laboratory, Space Electro-Optics Division's mission to advance the nation's space superiority capabilities. Work will be performed at Albuquerque, New Mexico, and is expected to be completed by October 20, 2033. This contract was a sole source acquisition. FY24 research, development, test and evaluation funds in the amount of $13.53M are being obligated at time of award. Air Force Research Laboratory is the contracting activity.

17:10 EDT Vision Sensing Acquisition Corp trading resumes

16:47 EDT U.S. Bancorp vice chair Richard sells 25,000 common shares - In a regulatory filing, U.S. Bancorp vice chair Jodi Richard disclosed the sale of 25,000 common shares of the company on October 18 at a price of $49.03 per share.

16:43 EDT United Airlines COO sells $1.04M in common stock - In a regulatory filing, United Airlines disclosed that its COO Torbjorn Enqvist sold 14.5K shares of common stock on October 17th in a total transaction size of $1.04M.

16:37 EDT Rayonier Advanced Materials announces power restored to Georgia site - Rayonier Advanced Materials announced that power has been fully restored to its Jesup, Georgia site and that the A Line has restarted operations. The A Line, which primarily produces cellulose specialties for use in filtration, food and pharmaceuticals, and tire cord, is currently operating at approximately 80% capacity, with an anticipated ramp-up to full capacity within a week. Repair work on the B line is ongoing and is expected to be completed with a restart on or around October 28. The company continues to assess the financial cost of the incident along with any potential insurance recovery. Further financial updates will be provided during its third-quarter earnings call in early November.

16:33 EDT JBDI Holdings regains compliance with Nasdaq - JBDI Holdings announced that as a consequence of not having filed its Annual Report on Form 20-F for the fiscal year ended September 30, prior to the filing deadline, the company received a deficiency notice from Nasdaq confirming that it was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the SEC. The company filed its Form 20-F with the SEC and received a notice of compliance from Nasdaq with Nasdaq Listing Rule 5250(c)(1).

16:25 EDT Vision Sensing Acquisition Corp trading halted, news pending

16:24 EDT Equity Lifestyle sees FY25 rate increase up 5% - The company said, "By October month-end, we anticipate sending 2025 rent increase notices to approximately 50% of our MH residents. The average expected rate increase of these notices is approximately 5.0%. We have set RV annual rates for 2025 for more than 95% of our annual sites. The average rate increase for these annual sites is approximately 5.5%."

16:22 EDT DMC Global chairman David Aldous steps down, James O'Leary to succeed - DMC also announced that director James O'Leary has agreed to serve as executive chairman, director Ouma Sananikone has been appointed lead independent director, and David Aldous has stepped down as DMC's independent chairman and as a member of the board. In addition, Peter Rose has decided not to stand for re-election at the company's next annual meeting of stockholders. O'Leary joined the board in November 2023 with nearly four decades of executive leadership, finance, capital markets and board-level experience.

16:21 EDT Simpson Manufacturing sees FY24 CapEx $175M-$185M vs. prior $180M-$190M - The company has updated its 2024 financial outlook based on three quarters of financial information to reflect its latest expectations regarding demand trends, cost of sales, and operating expenses. Based on business trends and conditions as of today, October 21, 2024, the company's outlook for the full fiscal year ending December 31, 2024 is as follows: Based on current expectations that U.S. housing starts will be down from the prior year, operating margin is estimated to be in the range of 19.0%-19.5%. The effective tax rate is estimated to be in the range of 25.3%-25.8%, including both federal and state income tax rates as well as international income tax rates, and assuming no tax law changes are enacted. Capital expenditures are estimated to be in the range of $175M-$185M, which includes $90M-$100M for the Columbus, Ohio facility expansion and the new Gallatin, Tennessee fastener facility construction with the remaining spend carrying over into 2025.

16:18 EDT Euroseas in 3-yr chartered deals for 3 2,800 teu feeder containership - Euroseas announced new time charter contracts for three fuel efficient 2,800 teu feeder containerships. All three charters are for a minimum period of 34 months and a maximum period of 36 months at the option of the charter at a gross rate of $32,000 per day. M/V Tender Soul, which was delivered earlier this year, will commence its charter after the completion of her present charter in early December 2024. M/V Dear Panel and M/V Symeon P, which are currently under construction, and represent the last two of the Company's nine-vessel newbuilding program, will commence their charters upon delivery from the shipyard, expected in the first week of January 2025. Aristides Pittas, Chairman and CEO of Euroseas commented: "We are very pleased to announce new time charter contracts for three of our modern 2,800 teu vessels - M/V Tender Soul and the last two upcoming newbuildings, MV/ Dear Panel and M/V Symeon P - with a top-tier charterer for 34-36 months at a very profitable rate of $32,000/day/vessel. "

16:16 EDT Revolution Medicines: 1st patient dosed in RMC-6236 study for PDAC treatment - Revolution Medicines announced that the first patient has been dosed in RASolute 302, a Phase 3 registrational study of RMC-6236, a RAS multi-selective inhibitor, in patients with previously treated, metastatic pancreatic ductal adenocarcinoma PDAC ..."Treating the first patient in RASolute 302 is a significant milestone for Revolution Medicines as we seek to revolutionize treatment for patients with RAS-addicted cancers," said Mark A. Goldsmith M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "RMC-6236 is designed to directly inhibit RAS(ON) signaling, which is the primary oncogenic driver of pancreatic cancer. Supported by the encouraging initial PFS and OS observations and safety profile reported from the Phase 1 RMC-6236 monotherapy trial, the randomized RASolute 302 trial will formally assess the potential for this bold investigational drug to make a meaningful difference for people living with metastatic PDAC, one of the most difficult-to-treat cancers."

16:11 EDT SAP reports current cloud backlog of EUR 15.4B, up 25% and up 29% at CC

16:09 EDT SAP updates 2024 cloud and software revenue outlook - For 2024, SAP is updating its cloud and software revenue, operating profit and free cash flow outlook and now expects: EUR 29.5 - 29.8 billion cloud and software revenue at constant currencies (2023: EUR 26.92 billion), up 10% to 11% at constant currencies, raising the midpoint by EUR 400 million. The previous range was EUR 29.0 - 29.5 billion at constant currencies. EUR 7.8 - 8.0 billion non-IFRS operating profit at constant currencies (2023: EUR 6.51 billion), up 20% to 23% at constant currencies, raising the midpoint by EUR 150 million. The previous range was EUR 7.6 - 7.9 billion at constant currencies. EUR 3.5 - 4.0 billion free cash flow (2023: EUR 5.09 billion). The previous outlook was approximately EUR 3.5 billion. SAP continues to expect: EUR 17.0 - 17.3 billion cloud revenue at constant currencies (2023: EUR 13.66 billion), up 24% to 27% at constant currencies. An effective tax rate of approximately 32% (2023: 30.3%).

16:08 EDT SAP reports Q3 cloud revenue EUR 4.35B vs. EUR 3.47B last year

16:07 EDT ServisFirst reports Q3 net interest margin 2.84% vs. 2.64% last year - Reports Q3 loan loss provision $5.6M vs. $4.3M last year.

16:04 EDT Powell Max CFO Chun Ho Lam resigns, Kam Lai Kwok succeeds - Powell Max announced the resignation of Chun Ho Lam as the CFO of the company due to personal reasons. The company has appointed Kam Lai Kwok as the new CFO. Prior to her joining of the company, Kwok served as an executive director of a Hong Kong listed company principally engaged in financial communications and financial printing services and as a financial controller of its operating subsidiary for over eight years.

15:05 EDT Truist pays over $9M to resolve allegations concerning SunTrust, DOJ announces - Truist Bank has agreed to pay the United States $9,125,000 to resolve claims under the Financial Institutions Reform, Recovery and Enforcement Act of 1989, or FIRREA, in connection with the administration of certain trust accounts by SunTrust Bank from December 2011 through December 2015, the Department of Justice announced.. SunTrust was acquired by Branch Banking and Trust Company in December 2019, and the combined entity was renamed Truist. Reference Link

14:27 EDT Fitell Corp trading resumes

14:21 EDT TC Biopharm (Holdings) PLC - ADR trading resumes

13:59 EDT Tevogen says CSO share sale 'solely' to satisfy payment of tax obligations - Tevogen Bio reported last week that Chief Scientific Officer Dr. Neal Flomenberg sold shares. "Tevogen's Chief Financial Officer, Kirti Desai, clarified that the sale was made solely to satisfy the payment of tax obligations relating to the vesting of restricted stock units and was not made at the discretion of the CSO. Other officers, the Chief Executive Officer, the Chief Financial Officer, and the Chief Commercial Officer, who hold more than 75% of total outstanding shares in aggregate, have already paid taxes when shares were granted and have no further obligation to make similar share sales. Additionally, none of the company's officers have decreased their holdings since the company's inception. In a related update, Tevogen Bio recently released top-line revenue projections for its oncology therapeutic area, anticipating $1 billion in revenue in the launch year for its lead product candidate, with a cumulative 5-year estimate ranging between $10 billion and $14 billion. The company plans to release similar revenue forecasts for its non-oncology therapeutic areas in the coming days," the company stated. "The leadership team's retention of 100% of their equity reflects our collective confidence in the company's potential. With over half a billion shares traded on the open market last week, I am deeply grateful for the public's unprecedented support of Tevogen's innovative business model," added Tevogen CEO Dr. Ryan Saadi.

13:49 EDT Hypera confirms acquisition proposal received from EMS - Hypera Pharma, in compliance with current regulations, informs that on this date it received a proposal for a public offer for the acquisition of shares and a combination of business of NC Farma Participacoes S.A., under the terms of the attached proposal. "The Council of Management will take steps to diligently evaluate the Proposal, including hiring external advisors. The Company will communicate to the market any updates on the topic," the company stated in its notice to the market. Reference Link

13:22 EDT Knightscope Inc trading resumes

13:07 EDT Oculis accelerates patient enrollment for both Phase 3 DIAMOND trials - Oculis Holding AG announces the acceleration of patient enrollment for both Phase 3 DIAMOND trials of OCS-01 eye drops in DME and expansion of the DIAMOND program committees with globally renowned retina experts. "Substantial enrollment progress was achieved since the end of Q2 2024 through early October, with 70% of patients enrolled in the Phase 3 DIAMOND-1 trial, and 40% of patients enrolled in the Phase 3 DIAMOND-2 trial. The DIAMOND (DIAbetic Macular edema patients ON a Drop) program consists of two Phase 3, double-masked, randomized, multi-center trials which will evaluate the efficacy and safety of OCS-01 eye drops in patients with DME," the company stated. Riad Sherif, M.D., Chief Executive Officer of Oculis, said: "We are very pleased with the strong momentum in patient enrollment in DIAMOND-1 and DIAMOND-2 Phase 3 trials which continues to exceed our expectations. We are also honored to have such a distinguished and broad group of global experts on the expanded DIAMOND program committees and look forward to working with the committees and benefiting from their deep expertise as we advance the DIAMOND program."

13:00 EDT Moderna sued by Northwestern University over vaccine patents - Zylem Biosciences announced that Northwestern University has filed a lawsuit against Moderna, alleging infringement of key patents related to mRNA vaccine technologies. The lawsuit, filed on October 16, in the United States District Court for the District of Delaware, asserts that Moderna "has unlawfully utilized patented Lipid Nanoparticle technologies developed at Northwestern University. These technologies have been critical to the success of mRNA vaccines, including those used in combating COVID-19 and respiratory syncytial virus." According to the claim, Moderna's use of these LNP technologies infringes on multiple patents owned by Northwestern University and licensed to Zylem Biosciences, the company said. The lawsuit seeks damages "to prevent further unauthorized use of the patented innovations but does not seek any injunctive relief."

12:14 EDT GE HealthCare announces CareIntellect for Oncology application - GE HealthCare announced CareIntellect for Oncology, a new cloud-first application that brings together multi-modal patient data from disparate systems into a single view, using generative AI to summarize clinical notes and reports. The application also surfaces relevant data allowing care teams to quickly understand disease progression and flag potential deviations from the treatment plan to help the clinician determine potential next steps and inform proactive interventions, the company said. The application, which is planned to be available to customers in U.S. next year, will initially focus on prostate and breast cancer, it added.

12:01 EDT Oklo rises 10.8% - Oklo is up 10.8%, or $1.97 to $20.20.

12:01 EDT Virgin Galactic falls -8.2% - Virgin Galactic is down -8.2%, or -63c to $7.08.

12:00 EDT Citizens falls -13.3% - Citizens is down -13.3%, or -78c to $5.08.

11:33 EDT Coherent appoints Rob Beard as chief legal and global affairs officer - Coherent Corp. (COHR) announced that following a comprehensive search, it has appointed Rob Beard as the company's new Chief Legal and Global Affairs Officer, and Corporate Secretary, effective today. Rob replaces current Chief Legal Officer Ron Basso, who is retiring. The company has also promoted Marie Batz Martin to Chief Compliance Officer, reporting to Rob. Beard joins Coherent from Mastercard (MA), where he was Chief Legal and Global Affairs Officer. "We are pleased to welcome Rob to Coherent's leadership team," said Jim Anderson, CEO. "His broad experience in the semiconductor industry, international policy experience, and expertise in business and law make him an excellent partner and counselor to help us unlock Coherent's full potential."

11:09 EDT Norfolk Southern announces tentative collective bargaining agreement with IBEW - Norfolk Southern announced that it has reached a tentative five-year collective bargaining agreement with the International Brotherhood of Electrical Workers, or IBEW. "The most recent agreement pushes the coverage of the union workforce under early tentative deals to approximately 67%. The agreement, which is subject to ratification, arrives in advance of the next collective bargaining round, providing covered employees with assurances that they will receive significant upcoming improvements to their pay, healthcare, and vacation benefits," the company stated. "Norfolk Southern is committed to working with all of our labor unions to ensure that our craft railroaders receive the best possible pay and benefits for the contributions they make every day to power the American economy. We're delighted to reach this new tentative agreement with IBEW so that we can reward these employees, without delay, for the critical work they do to keep the steel wheels rolling," said Mark George, Norfolk Southern President and CEO.

10:21 EDT Hefner Capital offers $100M plus equity for Playboy brand, Bloomberg reports - Hefner Capital, a firm led by Cooper Hefner, son of Playboy founder Hugh Hefner, has expressed interest in acquiring the Playboy brand from PLBY Group, people with knowledge of the matter told Bloomberg's Gillian Tan. Cooper Hefner made the non-binding overture for all of Playboy's brand assets, which includes intellectual property associated with Playboy, to PLBY's board, led by Chairman Suhail Rizvi, on Monday, according to a correspondence reviewed by Bloomberg News. The proposal, which is subject to due diligence among other considerations, involves Hefner forming an entity to purchase Playboy's brand assets from PLBY for a cash payment of $100M as well as a 10% equity interest in the new entity, the report noted.

10:03 EDT OLB Group announces S-1 filing for proposed spin-off of DMint - OLB Group has filed a Form S-1 with the Securities and Exchange Commission relating to the proposed spinoff of its wholly owned subsidiary, DMint, a Bitcoin mining facility, to OLB shareholders. Shareholders of record on the to-be-announced date will receive shares in the newly independent DMint. The shareholder record date for the spinoff has yet to be determined and will be announced at a future date. The company said, "DMint operates as a dedicated Bitcoin mining facility in Selmer, TN with a focus on sustainability and efficiency. The spinoff will allow DMint to operate independently, providing shareholders with direct exposure to the fast-evolving cryptocurrency sector. The company employs advanced technology and energy-efficient strategies to enhance mining productivity while minimizing environmental impact. We believe the public filing of the S-1 represents a significant milestone in the spinoff process, underscoring OLB's commitment to delivering value to its shareholders through innovative strategies and cutting-edge ventures in the digital currency space."

10:00 EDT VF Corp. falls -6.5% - VF Corp. is down -6.5%, or -$1.27 to $18.32.

10:00 EDT Associated Capital falls -7.1% - Associated Capital is down -7.1%, or -$2.90 to $38.20.

10:00 EDT Lumen rises 9.3% - Lumen is up 9.3%, or 62c to $7.37.

09:49 EDT DRAGON PHARMA INC trading resumes

09:48 EDT Skillsoft falls -9.2% - Skillsoft is down -9.2%, or -$1.51 to $14.85.

09:47 EDT Oklo rises 7.8% - Oklo is up 7.8%, or $1.43 to $19.66.

09:47 EDT Viad rises 25.7% - Viad is up 25.7%, or $9.18 to $44.96.

09:42 EDT Stilwell to vote in favor of proposal to sell IF Bancorp - Stilwell Activist Investments, L.P., one of the largest stockholders of IF Bancorp, issued a statement in connection with the company's upcoming annual meeting of stockholders scheduled to be held on November 25, at which stockholders will vote on a number of matters, including Stilwell's non-binding proposal requesting a sale of the company, submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended: "Based on chronic underperformance and the likelihood of continued underperformance, we intend to vote FOR the Proposal, at the upcoming Annual Meeting. Proposal: RESOLVED, that the stockholders of IF Bancorp hereby recommend that the Board of Directors take all necessary steps to promptly effectuate a sale of the Company. As set forth in our Supporting Statement included in IROQ's proxy statement filed with the Securities and Exchange Commission on October 16, we believe that the returns on the Company's assets have been subpar for many years and that IROQ stockholders would be best served if the Company and its assets were sold at the earliest opportunity for the highest price available. Although our proposal is non-binding, we believe it provides a referendum for IROQ stockholders to express their views on the status quo and that it would be incumbent upon the Board of Directors to seriously consider such views if a majority of stockholders support this Proposal at the Annual Meeting."

09:30 EDT Genenta Science SPA (ADR) trading halted, volatility trading pause

09:26 EDT PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA - PharmAla Biotech Holdings has been contracted as a supplier of its GMP LaNeo MDMA to a clinical trial at Mt. Sinai Health System.

09:18 EDT Sealsq says offering 'most comprehensive' Root of Trust solution - The company said, "SEALSQ Corp announces that its fully integrated Root of Trust provides one of the most complete security solutions on the market, a unique offering that covers both PKI and hardware. Using SEALSQ's RoT solutions, businesses and organizations can trust their digital operations at every level, from cryptographic key management to device-level security. SEALSQ is one of the few players in the industry to provide such a holistic approach, integrating the entire security stack for a comprehensive solution."

09:16 EDT Walmart reaches opioid shareholder settlement - Walmart announced that it has reached a proposed settlement agreement about its distribution of prescribed opioids, according to a filing with the U.S. Securities and Exchange Commission on Friday. As the company has previously disclosed, three shareholders of the company filed a derivative action in the Delaware Court of Chancery alleging that certain current and former directors and officers breached their fiduciary duties by failing to adequately oversee the company's distribution and dispensing of prescription opioids. This action is Ontario Provincial Council of Carpenters' Pension Trust Fund, et al. v. Walton, et al., Delaware Court of Chancery, Case No. 2021-0827-JTL. Also as previously disclosed, other shareholders of the company filed two derivative actions alleging that certain current and former directors and officers breached fiduciary duties and violated federal securities laws in connection with the company's distribution and dispensing of prescription opioids. These actions are Abt v. Alvarez, et al., U.S. District Court for the District of Delaware, Case No. 21-cv-00172-CFC and Nguyen v. McMillon, et al., U.S. District Court for the District of Delaware, Case No. 21-cv-00551-CFC. On May 5, 2023, the Walmart Board of Directors adopted resolutions creating a special litigation committee to investigate, review, and analyze the facts and circumstances surrounding the claims and allegations in the Derivative Actions and determine whether the prosecution of such claims is in Walmart's best interest. The parties to the Ontario Action and the Special Litigation Committee have reached an agreement that would resolve the Derivative Actions and release other potential derivative claims. If the Delaware Court of Chancery approves the proposed settlement: (i) insurance carriers would pay the company $123M, less any attorneys' fees and litigation expenses awarded by the Court to plaintiffs' counsel; and (ii) the company would maintain certain corporate governance practices for a period of at least five years. The settlement does not include any admission of liability, and the defendants expressly deny any wrongdoing. The terms and conditions of the proposed settlement are contained in the Stipulation and Agreement of Settlement, Compromise, and Release.

09:15 EDT Inhibikase Therapeutics closes up to $275M financing, advances IkT-001Pro - Inhibikase Therapeutics announced the closing of a private placement of approximately $110 Million from the issuance and sale of shares of the Company's common stock and accompanying warrants with potential aggregate financing of up to approximately $275 Million upon the full cash exercise of the warrants issued in the private placement, before deducting placement agent fees and offering expenses. The financing will fund execution of the Phase 2b '702' trial in Pulmonary Arterial Hypertension and for general corporate purposes. Concurrent with the closing of this financing, three leaders in biopharmaceutical development and a Partner of Soleus Capital with deep experience in financing cardiopulmonary therapeutics development will join the Board of Directors at the closing of this transaction. Roberto Bellini, former CEO of BELLUS Health and current Managing Partner of BSQUARED Capital, Amit Munshi, current CEO of Orna Therapeutics and former CEO of Arena Pharmaceuticals, Arvind Kush, current CFO of Candid Therapeutics and former CFO of RayzeBio and David Canner, Partner at Soleus Capital, have been appointed to the Inhibikase Board of Directors. In addition to joining the Board of Directors, Messers. Bellini, Munshi and Kush will each participate in the transaction. Mr. Bellini has been appointed Independent Chairperson of the Inhibikase Board coincident with the closing. In addition to these new Board members, Ms. Gisele Dion, Chair of the Audit Committee and Dr. Paul Grint, Chair of the Compensation Committee, have resigned from their service on the Board.

09:15 EDT SecureWorks trading resumes

09:14 EDT T-Mobile, Miller Electric collaborate on private network - T-Mobile and Miller Electric Company announced a collaboration to use a 5G private network to connect a fleet of autonomous vehicles, or AVs, along the city's waterfront and urban core as part of Jacksonville's Ultimate Urban Circulator program. Jacksonville-based Miller Electric will use a 5G private network from T-Mobile's Advanced Network Solutions to support the operations of the new bus-shaped, fully autonomous shuttles that will transport visitors along a three-mile stretch from the home of the city's professional football team, EverBank Stadium, to the new waterfront hub.

09:12 EDT INVO Bioscience confirms name change, new trading symbol following NAYA merger - INVO Biosciences confirmed it has changed its corporate name to NAYA Biosciences Inc. and will begin trading under the new symbol "NAYA" at the market open on Tuesday, October 22, 2024. The CUSIP number for the Company's common stock will remain unchanged. The name and symbol change follows the Company's recent announcement on October 14th regarding the completion of its merger with NAYA Biosciences. The newly combined company will continue to operate the revenue-generating fertility business while expanding its focus on the development of first-in-class clinical-stage assets in oncology and autoimmune diseases.

09:10 EDT Kartoon Studios announces Stan Lee's The Excelsiors set for development - Kartoon Studios, the controlling partner of Stan Lee Universe, announced the development plans for Stan Lee's The Excelsiors - one of the largest initial superhero ensemble creations by the legendary Stan Lee. The project will launch as a graphic novel through Legible Comics, with concurrent development for television and film adaptations. Stan Lee's The Excelsiors will be brought to life by one of the most successful names in the superhero genre - Michael Uslan - Originator and Executive Producer of the Batman film franchise.

09:08 EDT Arteris, SiFive announecs availability of pre-verified solution - Arteris and SiFive announced the availability of the pre-verified solution to enable the development of high-performance applications in the datacenter market without the risk. The combination of the SiFive P870-D CPU and Arteris Ncore cache coherent interconnect IP accelerates the path for SoC design engineers to address the demanding AI workload requirements of the datacenter and embedded systems markets. SiFive's P870-D CPU enables high compute density and supports the open AMBA CHI protocol so customers have more flexibility to scale the number of clusters to boost performance while minimizing power consumption.

09:06 EDT Cero Therapeutics submits IND clinical hold CRL to the FDA - CERo Therapeutics provides the following corporate update to stockholders from Interim CEO Chris Ehrlich, "Following the events of the last several months, I believe it appropriate to discuss our recent progress and illuminate the path forward for CERo. As you know, we received notice of a clinical hold for CERO-1236 earlier this year. Since then, we have been diligently working to complete the experimental studies necessary to address and resolve the U.S. Food and Drug Administration's questions. We recently completed communications with the FDA, in which we were able to gain feedback on our approach to addressing the Agency's questions. We have now submitted our Complete Response Letter to the Agency and look forward to what we hope will be the authorization to begin human trials. That said, given the blocks of time between submission to the Agency and their expected 30-day response time, we feel it is more realistic to adjust our previous guidance about potential entry into the clinic from 2024 to early 2025. We are also very pleased to have made important changes to our management team and Board of Directors. As previously announced, Al Kucharchuk has joined as our new CFO. Al is well versed in the unique challenges associated with small and microcap life sciences companies in the public markets, having deep experience in both since 2006. In addition, as previously announced, we have promoted Kristen Pierce to the position of Chief Development Officer. Kristen has deep expertise in the management of preclinical oncology programs and has been instrumental in our development of CERO-1236. We believe that that our team is well-positioned to help drive our science and our business forward. We have also made several changes to our Board of Directors, which we believe will enhance our execution of our business plan and we are well-positioned to do so. Finally, we recently disclosed our cash balance of $3.2 million as of September 30, 2024, which we are optimistic should provide sufficient runway to execute on our strategy. I anticipate providing an update on FDA's determination whether to release the clinical hold, as well as our path forward in the coming weeks and months and remain excited for the future of CERo. Thank you for your continued interest in our company, and the trust you continue to show both our management and our science."

09:05 EDT Beacon teams with GAF to add ecommerce feature GAF QuickMeasure - Beacon announced a partnership with GAF to provide its customers access to now order GAF QuickMeasure reports from Beacon PRO+ an industry-leading digital platform. Beacon PRO+...Beacon's integration with GAF provides contractors with another option to take the guesswork out of the estimation process by ordering QuickMeasure reports to get fast and accurate roof measurements. "This is a much more convenient and cost-efficient way for our customers to access property owner's roof details and images," said Jamie Samide, Beacon's Vice President of Marketing. "Continued investment in our digital platform increases customer loyalty and enhances profit margin, both of which help drive above market growth in line with our Ambition 2025 strategy."

09:04 EDT Hydromer, Inc. forms new Research and Development division - Hydromer announced the formation of a new Research and Development division. This restructuring introduces a science team focused on innovation and performance, adding two Ph.D. chemists and one M.S. chemist. Leading the team is Dr. Yonghua Zhou, Ph.D. in Polymer Science from the University of Massachusetts at Lowell. Dr. Zhou brings an impressive background in polymer science, having led new product development activities at InnoPoly Biotech, Kraton Polymers, and Innovia LLC. Joining Dr. Zhou in forming the company's new research and development team are Mr. Ashutosh Upadhyay and Ms. Mengxue Zhang. Mr. Upadhyay brings over 30 years of polymer science experience, including serving for more than 15 years as Senior Material Development Chemist at Dana Corporation. Ms. Zhang, a Ph.D. in Chemistry from the University of South Carolina, and M.S. in Polymer Engineering from the University of Akron, focused her studies on controlling nanoparticle distribution within polymer coatings. Under its new executive leadership, Hydromer has refocused its efforts on improving financial reporting and record-keeping, enhancing operational efficiencies, and advancing the science behind its current and future coating technologies. Recognizing the need for both product improvement and innovation to meet customer demands, the company has assembled this highly credentialed team to revitalize legacy products and create new solutions for evolving market needs. With Dr. Zhou's experience and leadership, the R&D team aims to develop advanced coatings that are both more durable and environmentally friendly, addressing the growing regulatory restrictions surrounding harmful solvents.

09:03 EDT GSE Systems and Pelican Energy Partners increase merger consideration - GSE Solutions has entered into an amendment to the merger agreement with an affiliate of Pelican Energy Partners announced on August 8. Pursuant to the amended merger agreement, GSE's common stock outstanding immediately prior to the effective time of the merger will be converted into the right to receive $4.60 per share in cash. This represents an increase of approximately 12.2% over the $4.10 of per share merger consideration previously agreed to by GSE and Pelican. In addition, the new per share merger consideration represents a premium of approximately 69% over the closing price of the GSE common stock as of August 7 and a premium of approximately 29% over the average 30-day volume weighted average price as of such date. GSE also announced that, as of October 18, the company held proxies representing 1,733,340 shares of stock, or 49.93% of the issued and outstanding shares.

09:02 EDT Biomea Fusion announces approval of 'icovamenib' as INN for BMF-219 - Biomea Fusion announced that the World Health Organization, WHO, has approved "icovamenib" as the International Nonproprietary Name, INN, for its lead product candidate BMF-219, and that the United States Adopted Name Council has adopted "icovamenib" as the United States Adopted Name, USAN, for BMF-219. The suffix '-menib' stands for menin inhibitor.

08:54 EDT enGene CTO Anthony Cheung transitions to CSO, Joan Connolly to succeed - enGene announced the appointment of Joan Connolly as CTO and member of the corporate leadership team. In addition, enGene co-founder and former CTO, Anthony Cheung, will transition to the role of chief scientific officer, or CTO, succeeding James Sullivan. Connolly's career spans more than 30 years, with experience across CMC development for large and small molecules, manufacturing management, regulatory filings, and product commercialization, as well as supply chain, logistics and sourcing, and procurement. In her most recent role, Connolly served as CTO of Albireo Pharma. Cheung is a co-founder of enGene and has served in various capacities since the company's inception.

08:46 EDT Stereotaxis' technology to be featured at SCRN Annual Meeting - Stereotaxis will participate in the Society for Cardiac Robotic Navigation's Annual Meeting taking place October 28-29 in Lisbon, Portugal. The global physician-led Society for Cardiac Robotic Navigation is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology. The SCRN conference includes a faculty of over forty physicians, including pioneering key opinion leaders in the field, from across North America, Europe, and Asia. Stereotaxis' robotic technologies will be highlighted in presentations, panels, and demonstrations throughout the conference. Topics range from the use and value of robotics across a range of clinical applications, new technology developments, and the broader context of robotics in endovascular interventions. Highlighted topics include: Developments with artificial intelligence, digitization of the operation room, and robotic automation; Clinical experience with the MAGiC ablation catheter and Abbott's EnSite X mapping system; Additional robotic catheter innovations including high-density mapping and pulsed field ablation; Robotic system innovations with Genesis and GenesisX; Alternative access from the arm rather than the groin; Clinical value and best practices for robotics in treating complex arrhythmia.

08:45 EDT SecureWorks trading halted, news pending

08:41 EDT Heico acquires 88% of Mid Continent Controls, terms not disclosed - HEICO Corporation's Electronic Technologies Group acquired approximately 88% of Mid Continent Controls for cash at closing. Key MC2 managers will continue to own the balance of the company. Additional financial details were not disclosed. HEICO stated that it expects the acquisition to be accretive to its earnings within the year following the acquisition. Derby, KS-based MC2 is a niche designer and manufacturer specializing in proprietary in-cabin power and entertainment components and subsystems for business jets. Its core products include power outlets, power distribution modules, cabin management systems, multimedia connectivity ports, seat controls and switch panels. MC2's products enhance the aircraft user experience, enabling passengers to mirror their ground experience in the air as they stay connected in flight. The company offers hundreds of different niche parts used on a wide range of business aircraft, while serving both new aircraft production and the aftermarket. Founded in 1996 by industry veteran Rick Hemphill, MC2 employs approximately 60 people at its Derby, KS engineering, production and testing facility. Rick Hemphill's son, Thomas Hemphill, will continue leading MC2 as its president, along with Mike Freel, MC2's General Manager. Thomas Hemphill and Mr. Freel will also remain company shareholders. Rick Hemphill will continue as a guiding consultant to MC2. HEICO stated that MC2 will operate from its Derby, KS location and that it does not expect material Team Member turnover to result from the acquisition. MC2 will report to HEICO's Radiant Power Group, which serves some of the same markets as MC2.

08:38 EDT DigitalBridge acquires majority stake in JTOWER for JPY 70.1B - DigitalBridge announced the completion of a tender offer for the common shares and the stock acquisition rights of JTOWER Inc. The tender offer, which commenced on August 15 and concluded on October 10 was conducted through DB Pyramid, a special purpose entity owned by funds managed by DigitalBridge's investment management platform. The Offeror has acquired a 75.62% controlling interest in JTOWER for JPY 70.1B, marking a significant milestone in DigitalBridge's expansion into the Japanese digital infrastructure market. DigitalBridge plans to take JTOWER private, which will make the offeror and Cultive, an asset management company of JTOWER's Representative Director Atsushi Tanaka, the sole shareholders of JTOWER. The delisting of JTOWER is expected to be completed in Q1 2025.

08:38 EDT Wearable Devices unveils white paper on future of gesture control - Wearable Devices announced the release of a landmark white paper titled, "Elevating AR Glasses User Experience with Gesture Control and Neural Wristband." The white paper provides an in-depth and definitive analysis of emerging trends in gesture control technology, comparing camera-based solutions with wearable neural interfaces that present a clear case for the future of seamless, wrist-worn input control. This sweeping industry and technology analysis draws on Wearable Devices' decade of experience developing pioneering human-computer interaction solutions, including the Company's Mudra Band, the world's first neural interface wristband. Wearable Devices' thought leadership highlights not only the current landscape of gesture control for face-worn devices but also identifies critical challenges and opportunities for improving usability, comfort and interaction quality. "Our far-reaching history in developing neural gesture-control technology uniquely positions Wearable Devices to provide this rigorous level of analysis," said CEO Asher Dahan. "Our Mudra technology represents a step forward in creating fluid and precise interactions with augmented reality glasses, eliminating the limitations of conventional input systems. This white paper offers key insights that help businesses and developers envision new ways to create user experiences where technology becomes an extension of natural human movement."

08:37 EDT Reborn Coffee launches latest patented coffeeware starting with Reborn Tumbler - Reborn Coffee announced the launch of its latest patented coffeeware, starting with the Reborn Tumbler. This product marks the beginning of a global rollout that is expected to drive significant growth and position Reborn Coffee at the forefront of the industry. The Reborn Coffee Tumbler, created exclusively for Reborn Coffee, was designed by Mr. Gu in collaboration with his design brand, Nooof. This innovative design, which earned the prestigious IF Product Design Award, seamlessly blends functionality and style in an eco-friendly tumbler, reflecting Reborn Coffee's dedication to sustainability and quality.

08:36 EDT Disney plans to announce next CEO in early 2026 - "A critical priority before us is to appoint a new CEO, which we now expect to announce in early 2026. This timing reflects the progress the Succession Planning Committee and the Board are making, and will allow ample time for a successful transition before the conclusion of Bob Iger's contract in December 2026," James Gorman said. The board's succession planning committee is chaired by Gorman and includes directors Mary Barra and Calvin McDonald, as well as Mark Parker until his departure. The committee and the full board continue to undertake a succession planning process, including evaluation of transition structures and organizational frameworks, and planning for potential impacts of succession decisions across the company. The Committee met six times in FY24, consistently engaging with the full board on the substance of the decisions to be made. The board discussed succession planning at each of its regularly scheduled meetings in FY24. The committee and board continue to review internal candidates and external candidates.

08:35 EDT Lumen, Meta Platforms announce partnership - Lumen Technologies (LUMN) and Meta (META) are partnering to significantly increase Meta's network capacity and help drive its bold AI ambitions. The expanded network will provide dedicated interconnection for Meta's industry-leading infrastructure, strengthening and increasing the company's ability to lead in AI development. This increase in capability is another differentiator that will fuel Meta's vision to advance AI for a more connected world. With the growing interest in AI, preparing for the future means investing in a reliable network. The Lumen partnership provides Meta with increased flexibility through secure on-demand bandwidth to support its complex computing needs and serve billions of people every day.

08:35 EDT Bright Minds, Firefly Neuroscience to collaborate after BREAKTHROUGH study - Bright Minds Biosciences (DRUG) announced that it is once again collaborating with Firefly Neuroscience (AIFF), an Artificial Intelligence company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, to provide a full analysis of the electroencephalogram data in the Company's BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy, DEE.

08:34 EDT Cryoport and TMRW Life Sciences partner for specimen management and transport - Cryoportand TMRW Life Sciences, a fertility technology company offering the highest standard of care in offsite storage for frozen eggs, embryos and sperm in the U.S. with the only FDA-cleared automated specimen management and storage platform, announced a strategic partnership to provide fertility clinics with complete solutions for secure specimen management and transport. Under this partnership, the biologistics and transport of specimens between the TMRW Biorepositories and fertility clinics will be handled by Cryoport Systems. Both TMRW and Cryoport are ISO-certified. TMRW is the only reproductive health storage provider with HIPAA-compliant, military-grade data security with SOC II and HITRUST certifications, along with cloud-based monitoring through Overwatch and its proprietary, cloud-based ivfOS software for digitally managing specimens. Cryoport brings over a decade of experience in reproductive medicine biologistics including tracking and visibility via its validated Cryoportal Logistics Management Platform.

08:34 EDT Disney chairman Mark Parker to depart, James Gorman to succeed - Disney's (DIS) board of directors has named James Gorman as chairman of the board, effective January 2, 2025. He will succeed Mark Parker, who is departing the Disney board on January 2 after nine years of service. Gorman is executive chairman of Morgan Stanley (MS) and, as previously announced, will be stepping down from that role on December 31. He is currently chair of the Disney board's succession planning committee, which is working to identify and prepare the next chief executive officer of Disney.

08:32 EDT IceCure Medical granted patent by USPTO for cryoablation system - IceCure Medical has received a Notice of Allowance for its invention titled "Cryogenic System Connector" from the USPTO. This is the first global patent issued for the cryogenic system connector, a key component of IceCure's next-generation liquid nitrogen-based XSense cryoablation system. Several other patent applications for this technology are pending in key markets. XSense and its cryoprobes, which have FDA clearance for all of the indications for which IceCure's flagship ProSense has already received clearance, has the potential to address additional indications and significant unmet needs in the global tumor ablation market, estimated at $1.67B in 2023 according to Grand View Research.

08:31 EDT Snail regains Nasdaq compliance - Snail announced that the company received written notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market informing the company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. To regain compliance with Nasdaq Listing Rule 5550(a)(2), the company was required to maintain a minimum closing bid price for its Class A common stock of $1.00 per share or more for at least ten consecutive business days.

08:23 EDT Nitches, Inc. preapres for Phase One Testing for InTheZone Labs products - Nitches announced the next big step in the evolution of its InTheZone Labs division. The company said, "As we prepare for Phase One Testing of our game-changing bioceutical products, we are inviting everyone to visit InTheZoneLabs.com to learn more about how these cutting-edge formulas can help unlock focus, vitality, and cognitive enhancement for users across a wide range of needs. InTheZone Labs is not just a supplement line-it's a movement toward better health, sharper focus, and elevated performance. We've spent months developing precision formulations that address common challenges from mental fog and physical fatigue to cognitive underperformance and reproductive health... InTheZone Labs is now gearing up for Phase One Testing to gather critical insights from real-world users across three key groups. We are dedicated to perfecting our products, and this phase is an essential step in gathering feedback that will help shape the future of InTheZone Labs: 1. Veterans and Their Families: We are proud to announce that veterans from various branches of service will be part of this groundbreaking study. Our focus will be on the effects of InTheZone Focused and InTheZone Passion in enhancing cognitive performance, mental clarity, and vitality among veterans. Additionally, we will be extending testing of InTheZone Youth to the children of veterans to evaluate its impact on focus and cognitive development in younger age groups. Their feedback will help refine our products for these unique and vital demographics. 2. Medical and Chiropractic Expertise: Two key leaders will be heading separate verticals in our testing process-a Medical Doctor and a Doctor of Chiropractic. These prominent figures, each leaders in their respective fields, will help test our products within their networks, gathering insights from individuals in medical and holistic healthcare. Their evaluations will give us a deeper understanding of how our supplements perform across different health contexts, ensuring our formulas continue to meet the highest standards of efficacy. 3. NFLPA Former Players: Former NFL players bring a unique perspective and challenge when it comes to maintaining cognitive and physical health post-career. Many have experienced CTE or other injuries, making them ideal participants for testing InTheZone Focused and InTheZone Passion. We believe the results from this group will offer critical insights, demonstrating the effectiveness of our products for high-performing individuals and providing a real-world basis for anyone interested in taking their health to the next level."

08:21 EDT CACI awarded $805M task order for engineering support for U.S. NavalX Office - CACI International announced that it has been awarded a five-year task order valued at up to $805M to provide engineering support and technology to the U.S. Navy's NavalX Office under the Department of Defense Information Analysis Center's DoD IAC multiple-award contract MAC vehicle. "As threats against our nation's security continue to grow in number and sophistication, so do the needs to address critical capability gaps, drive innovation, and solve complex problems," said John Mengucci, CACI President and Chief Executive Officer. "CACI's six-plus decades of supporting Navy programs gives us the experience needed to tackle the most pressing challenges our sailors face every day by developing new technology and capabilities, and delivering them rapidly fleet-wide to increase readiness and effectiveness." Under this task order, CACI will perform research, analysis, engineering, prototyping, and assessments to identify, develop, test, and transition modern digital tools for the Navy. CACI will also connect teams with tools, training, and resources that will deliver more indispensable solutions to the warfighter. These activities will allow NavalX to enhance operational performance through advanced technology development and seamless integration of multi-domain systems.

08:19 EDT Microchip announces PIC64HX family of microprocessors - Microchip Technology has announced the PIC64HX family of microprocessors. Unlike traditional MPUs, the PIC64HX is purpose built to address the unique demands of intelligent edge designs. The latest in Microchip's 64-bit portfolio, the PIC64HX is a high-performance, multicore 64-bit RISC-V MPU capable of advanced Artificial Intelligence and Machine Learning processing and designed with integrated Time-Sensitive Networking Ethernet connectivity and post-quantum-enabled, defense-grade security. PIC64HX MPUs are specifically designed to deliver comprehensive fault tolerance, resiliency, scalability and power efficiency.

08:17 EDT Stingray Group partners with Xperi for eight new video channels - Stingray (STGYF) announces the launch of eight new video channels - Stingray Naturescape, Stingray Holidayscapes, ZenLIFE by Stingray, Qello Concerts by Stingray, Stingray Classica, Stingray CMusic, Stingray DJAZZ, and Ultimate Trivia by Stingray - on the DTS AutoStage Video Service Powered by TiVo (XPER). This strategic expansion is set to transform in-car entertainment by offering a diverse array of premium content to a wide range of vehicles in the current product portfolio of the BMW Group, providing a cohesive and comprehensive solution that caters to the evolving needs of modern car owners, drivers, and passengers. The DTS AutoStage Video Service Powered by TiVo is an AI-powered global entertainment platform designed for the connected car. It seamlessly integrates linear broadcast with IP-delivered content, creating a unified, user-centric experience that revolutionizes in-car entertainment. The video channels are now available in BMW Group vehicles across the United States, Great Britain, Ireland, Germany, France, Italy, Spain, South Korea, Austria, Switzerland and soon in more markets.

08:15 EDT First Onsite hires team of commercial restoration professionals in MA - First Onsite Property Restoration has expanded its presence in New England by hiring a team of seasoned and long-established commercial restoration professionals in Massachusetts. First Onsite's new team is led by 25-year restoration veterans Gary Grout and Jason Green. Most recently, Gary was the President and Jason was the Director of Operations of Complete Restoration Solutions, a full-service restoration company headquartered in Springfield, MA. Before CRS, Gary's experience included traveling the country to estimate and manage large and complex restoration projects and running a large restoration team that covered the East Coast. His industry expertise and tenacious client focus have earned him a loyal following among large commercial clients and large loss insurance adjusters, who often bring Gary in to consult on major projects. Jason has garnered his own reputation among clients for his expertise in many facets of restoration including estimating and managing large and complex jobs, as well as leaning on his business acumen to oversee back-office functions.

08:14 EDT Soleno Therapeutics announces passing of former chairman Ernest Mario - Soleno Therapeutics announced with deep sadness the passing of former Chairman of the Board of Directors, Ernest Mario, Ph.D, at the age of 86 years. Dr. Mario served as the Soleno's Chairman from 2007 through August 2024.

08:12 EDT Orgenesis commences trading on OTCQX Best Market - Orgenesis announced that its common stock will begin trading on the OTCQX Best Market under the ticker symbol "ORGS" following its delisting from the Nasdaq Stock Market. The delisting resulted from the Company's failure to meet the required stockholders' equity threshold. Orgenesis plans to attempt to resolve the deficiency and reapply for a Nasdaq listing as soon as practical.

08:11 EDT Madrigal Pharmaceuticals completes enrollment of study of Resmetirom - Madrigal Pharmaceuticals announced the MAESTRO-NASH OUTCOMES trial evaluating resmetirom for the treatment of patients with compensated NASH cirrhosis has completed enrollment. Bill Sibold, Chief Executive Officer of Madrigal, stated, "The MAESTRO-NASH OUTCOMES trial is important for patients and the NASH field more broadly because there is an urgent unmet need for therapies that can prevent progression to the devastating complications of decompensated cirrhosis and by extension reduce the need for liver transplants due to NASH... Today's enrollment milestone brings us one step closer to our goal of delivering the first effective therapy to patients who currently have no approved treatment options for compensated NASH cirrhosis. A positive outcome for this study is also expected to support the full approval of Rezdiffra for noncirrhotic NASH."

08:10 EDT Lenz Therapeutics announces FDA acceptance of NDA for LNZ100 - LENZ Therapeutics announced that the U.S. Food and Drug Administration, FDA, has accepted the Company's New Drug Application, NDA, for LNZ100 for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The FDA has assigned a Prescription Drug User Fee Act, PDUFA, target action date of August 8, 2025 for LNZ100. The FDA noted that it is not planning to hold an advisory committee meeting to discuss this application. The NDA submission for the treatment of presbyopia is supported by the positive data results from the pivotal Phase 3 CLARITY study. Aceclidine is a new chemical entity in the United States and is not approved for the treatment of presbyopia in any country.

08:09 EDT Diebold announces development in partnership with Piraeus - Diebold Nixdorf announced a pivotal development in its long-standing partnership with Piraeus, a Greek multinational financial services company. By the end of 2024, Piraeus will have replaced its fleet of more than 1,200 self-service devices located inside the bank's branches with DN Series cash recycling ATMs. The ATMs will provide Piraeus customers the ability to conveniently manage their cash while giving the bank a proven platform to move many transactions from inside the branch to the self-service channel in support of its branch transformation program.

08:07 EDT Dayforce launches 'Do the work you're meant to do' campaign - Dayforcevannounced the launch of its mass brand advertising campaign, 'Do the work you're meant to do.' Brought to life through television and out-of-home displays across the U.S., the campaign encourages viewers to harness simplicity at scale in their HR operations to achieve greater purpose and meaning within their work lives. This campaign falls on the heels of the company's announcement to unite its global brand as Dayforce. With a focus on helping organizations realize the full potential of their people, Dayforce continues to set a new standard for the HCM industry and help deliver quantifiable value to customers.

08:06 EDT Mainz Biomed restructured operations, implemented cost reductions - In September 2024, Mainz Biomed announced feedback received from the FDA for the breakthrough device designation with the request to expand the current clinical data set with additional average risk population. In October 2024, the Company made the strategic decision to focus its efforts on three key initiatives for the remainder of 2024 and into 2025 in order to maximize shareholder value. Those initiatives are: The continued growth of its ColoAlert business in Europe; Development of its next generation colorectal cancer screening product; and Running a 2,000 patient study, with average risk patients in the U.S., to read out in the second half of 2025. With eAArly DETECT 2, the Company addresses the recent FDA feedback and prepares for a new submission for breakthrough device designation with an expanded data set, including a larger average-risk patient population. In line with these strategic initiatives, the Company restructured its operations and implemented cost reductions which included decreasing its operating costs, primarily driven by the reduction of personnel and external consulting costs.

08:01 EDT Leidos awarded $331M contract from U.S. Army - Leidos was recently awarded a new contract to modernize the U.S. Army's network in alignment with the Army's Network Modernization Strategy and Army Unified Network Plan. The contract was awarded by the Army Program Executive Office for Command, Control and Communications-Tactical Global Enterprise Network Modernization-OCONUS. The contract has a one-year base period of performance with four one-year option periods. The contract has a total value of $331M if all options are exercised.

07:49 EDT MIRA says Ketamir-2 outperforms FDA-approved neuropathic pain treatments - MIRA Pharmaceuticals announced that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved treatments Gabapentin and Pregabalin. Ketamir-2, a non-opioid, offers tremendous promise for patients seeking better solutions for neuropathic pain without the habit-forming risks or debilitating side effects associated with existing medications. The latest preclinical study, conducted using a nerve ligation-induced neuropathy model in female rats, demonstrated that low doses of oral Ketamir-2 provided significant pain relief by Day 15. By Day 22, Ketamir-2 achieved up to 112% more effective results than Pregabalin and 70% greater relief than Gabapentin at higher doses. These findings build on prior studies in male rats, where Ketamir-2 fully reversed neuropathic pain, while oral ketamine showed no effect. This consistent efficacy across different models further highlights Ketamir-2's potential to deliver superior, effective relief through the oral route, positioning it as a promising alternative to current treatments. Ketamir-2 offers several key advantages over current treatments: Non-Habit Forming: Unlike Pregabalin, Ketamir-2 carries no known risk of dependence, making it safer for long-term use. Superior Pain Relief: The preclinical data shows that Ketamir-2 offers better efficacy than Pregabalin and better efficacy than Gabapentin. Fewer Cognitive Side Effects: With the potential to avoid sedation and cognitive impairment, Ketamir-2 offers an improved quality of life compared to currently available treatments. MIRA is actively preparing to launch preclinical trials for post-traumatic stress disorder, recognizing the urgent need for non-addictive treatments for PTSD. The growing mental health crisis highlights the need for effective alternatives to existing PTSD medications, and Ketamir-2 has the potential to fill that gap. The company is also actively pursuing government grants for PTSD and other indications, capitalizing on the increased public focus and funding initiatives aimed at mental health treatment. These grants could help accelerate the development and delivery of Ketamir-2 to patients suffering from PTSD, depression, and other neuropsychiatric conditions. MIRA is on track to submit an Investigational New Drug application for Ketamir-2 by the end of this year and is currently preparing for Phase 1 clinical trials scheduled to begin in the first quarter of 2025. The company aims to start Phase 2 trials in the last quarter of 2025, allowing for the first signs of human efficacy by the end of that year. As part of these preparations, MIRA is pursuing scientific publications to share progress and insights with the broader medical community. Ongoing preclinical studies are evaluating Ketamir-2's impact on chemotherapy-induced neuropathy, a condition that, if proven effective, could qualify the drug for FDA breakthrough designation, potentially shortening the regulatory timeline. The company is also conducting further studies for diabetic neuropathy, expanding the therapeutic potential of Ketamir-2.

07:36 EDT Origin Agritech establishes biotechnology service consortium - Origin Agritech announced the establishment of the "Origin Marker Biological Breeding Service Consortium" in partnership with China Golden Marker Biotechnology. This consortium is designed to license Origin's GMO insect-resistant and herbicide-tolerant traits to a wider range of industry players and to accelerate the application of Origin's gene editing technology in breeding programs. The consortium represents a significant step in advancing the commercialization of Origin's cutting-edge GMO and gene editing technologies. Following the company's receipt of a GMO safety certificate for its transgenic maize, BBL2-2, in May 2024, this consortium will play a key role in promoting the licensing of these GMO traits to seed companies and research institutes. In addition, Origin Agritech's gene editing technology, is central to the consortium's mission. By integrating this technology into Origin's breeding programs and its partners, the consortium seeks to accelerate product development while expanding the royalty opportunities for new, high-performing maize varieties. China Golden Marker Biotechnology is a high-tech biotechnology company specializing in next-generation sequencing, gene chip detection, and molecular marker technology.

07:33 EDT Generac selected for $50M award by Department of Energy - Generac has been selected to enter into negotiations by the Department of Energy - DOE - to receive an award for a grant of $50M as part of the DOE's Grid Resilience and Innovation Partnership - GRIP -. Established by the Bipartisan Infrastructure Law, the GRIP Program is a $10.5B investment to enhance grid flexibility, improve the resilience of the power system against extreme weather, and ensure American communities have access to affordable, reliable, energy when and where they need it. Generac, in collaboration with the California Water Association, aims to integrate clean energy solutions with water utilities statewide. The total investment is estimated to be approximately $100M across about 100 California water utility sites, particularly in Disadvantaged Communities. Under the project, microgrids, which will utilize battery energy storage and be managed by distributed energy resource management systems, will form virtual power plants capable of delivering reliable load reduction during times of grid stress. Additionally, the project, with at least 55% of sites in DACs, will lead to improved air and water quality, reliability, and operational savings. The project will create an estimated 200 union construction jobs and 33 direct jobs.

07:33 EDT Acacia Research acquires Deflecto Acquisition for $103.7M - Acacia Research announced that is has acquired Deflecto Acquisition for $103.7M. Headquartered in Indianapolis, Indiana, Deflecto is a specialty manufacturer of products serving the commercial transportation, HVAC and office markets. Under Acacia's ownership, Deflecto will continue to be led by Ross Pliska, CEO, and the existing Deflecto management team. Its products include emergency warning triangles and vehicle mudguards used by the transportation industry, various airducts and air registers used by the HVAC market and literature, sign holders and floormats used by the office market. Deflecto manufactures its products at nine manufacturing facilities across the United States, Canada, the United Kingdom and China. In the trailing twelve-month period ended August 31, Deflecto generated revenue of approximately $131M. Based on current market conditions and trends, Acacia expects Deflecto to generate approximately $128M-$136M in revenue in 2024. The transaction was funded utilizing cash on hand and borrowings under a new senior secured credit facility guaranteed by certain subsidiaries of Deflecto. Following distribution of the transaction proceeds, Deflecto will have approximately $48M outstanding under the facility and $10M of cash on hand.

07:33 EDT Trevi Therapeutics completes enrollment for Phase 2a RIVER trial - Trevi Therapeutics announced that it has completed enrollment in its Phase 2a trial for the treatment of RCC and expects to report topline data in the first quarter of 2025.

07:31 EDT MYnd Analytics announces $10M share repurchase program - Mynd.ai announced that the company's Board of Directors has authorized the repurchase of up to $10M of its American depositary shares and/or ordinary shares as market conditions and the company's liquidity warrant.

07:27 EDT Quantum BioPharma files lawsuit against CIBC World Markets, RBC Dominion - Quantum BioPharma announces the Company, on 20th October 2024, has filed a complaint in the United States District Court for the Southern District of New York alleging that CIBC World Markets, RBC Dominion Securities, and others engaged in market manipulation schemes that violated Section 10(b) and Rule 10b-5(a) and (c) and Section 9(a) of the Securities Exchange Act of 1934. This lawsuit alleges that between 1st of January 2020, and 15th of August 2024 the Defendants and/or their customers used "spoofing" techniques to manipulate the share price of Quantum BioPharma shares. The Company is seeking damages of more than $700M. The law firms Christian Attar and Freedman Normand Friedland have decided to take and file this case on a contingency basis, so there will be no material financial pressure on the Company to bear the legal costs associated with this case. These law firms, working with industry experts, conducted an extensive investigation into the Defendants' conduct, and have concluded that there is sufficient evidence of market manipulation for the Company to pursue claims against the Defendants. The complaint details this evidence, which the Company alleges demonstrates that Defendants "spoofed" the market hundreds of times, thereby artificially depressing the price of the Company's stock again and again and harming both the Company and its many retail investors. The Company's stock in January 2020 was trading over $460 per share with a market cap close to almost One Billion dollars. The Company's share price as of market close on Friday Oct 18th, 2024, was $7.55 per share with a market cap of less than $15M. The Company believes that, besides CIBC and RBC, there are other banks/brokers who are also involved in this alleged market manipulation scheme in the company's stock. The Company will refrain from naming them at this point until more conclusive evidence has been gathered. The Company is open to dialogue and will always remain open to finding an amicable solution with the banks and brokers involved.

07:21 EDT Prospect Capital upsizes preferred stock offering to $2.25B - Prospect Capital announced an upsize to Prospect's preferred stock offering with Preferred Capital Securities. The Offering has seen strong demand from the private wealth, institutional, and Registered Investment Advisor channels, with $1.8 billion in aggregate liquidation preference issuances since the initial closing in the quarter ending December 31, 2020. PCS is a securities broker dealer and the dealer manager for the ongoing offering of the Series A4 and M4 Preferred Stock. PCS has raised $5.0 billion of capital since its formation in 2011.

07:19 EDT Bombardier manufacturing major components for 1st Global 8000 jet - Bombardier announced that manufacturing of major structural components for the 1st Global 8000 production jet is underway across Bombardier facilities in Saint-Laurent, Red Oak and Queretaro. Set to enter into service in the second half of 2025, the Global 8000 private jet will stand alone as the world's fastest and longest-range purpose-built business jet, innovatively crafted with the smoothest ride and the industry's healthiest cabin. The aircraft also continues to impress in flight testing, achieving positive results throughout its campaign.

07:18 EDT Dorman Products announces release of hundreds of new aftermarket components - Dorman Products is announcing the release of hundreds of new aftermarket components and assemblies, adding to its expansive catalog of more than 133,000 SKUs. Several of these new offerings represent aftermarket exclusives, first-to-aftermarket solutions that help keep vehicles on the road for everyday drivers while providing millions of repair opportunities for parts distributors, retailers and repair shops.

07:16 EDT Seer showcases proteomic advancements at HUPO 2024 - Seer to present significant advancements at the 23rd Human Proteome Organization World Congress in Dresden, Germany, from October 20-24, 2024. As a HUPO sponsor, Seer will showcase novel findings that are driving the adoption and expansion of proteomic science, demonstrating the unique power of its Proteograph Product Suite to accelerate proteomic research at scale. Highlights from Seer at HUPO 2024: Alzheimer's Disease: Exploring Genetic Influence with Unbiased Proteogenomics to Uncover Unexpected Disease Pathways Title: Understanding the Impact of Genetic Variants on Alzheimer's Disease with Mass Spectrometry Proteogenomics: Leveraging Seer's Proteograph XT, this study analyzes almost 1,800 plasma samples from 1,005 participants of the Massachusetts General Hospital Alzheimer's Disease Cohort, exploring the connection between genetic variants and proteomic alterations associated with Alzheimer's Disease. By combining mass spectrometry-based proteomics and Mendelian randomization, this analysis uncovered 138 differentially abundant protein groups between healthy and Alzheimer's-affected individuals, pinpointing possible causal pathways linked to disease progression. This approach demonstrates how Seer's platform facilitates comprehensive coverage and effectively correlates genetic and proteomic data, providing an unbiased exploration of complex diseases. This research advances the understanding of systemic factors in Alzheimer's, potentially revealing new biomarkers and therapeutic targets that targeted methods might overlook. Population Health Studies: Achieving Population-Scale Plasma Proteomics with Novel Speed and Depth to Drive New Discoveries: Title: Empowering Robust Population-Scale MS Plasma Proteomics Studies with Nanoparticle Enrichment: Seer's Proteograph XT was applied in a population study involving 1,600 plasma samples, combining nanoparticle enrichment, plate-based automated preparation, and MS measurements to achieve significant depth at scale. With over 8,100 protein groups identified and processing throughput reaching 40 samples per day, the cloud-based DIA-NN integration accelerated data analysis up to twenty times faster compared to standard computational frameworks. By compressing the dynamic range of plasma proteins and enhancing peptide diversity, this workflow circumvents typical bottlenecks like manual fractionation and depletion, delivering higher coverage with minimized handling time. This capability is particularly valuable for discovery proteomics researchers looking to generate biological insights efficiently, offering significant gains in both depth and throughput. Whole Blood Microsampling: Extending Accessibility of Proteomics through Novel DBS Analysis for Comprehensive Biomarker Studies: Title: Advancement in Nanoparticle-Based Proteomic Analysis of Whole Blood Obtained from Various Dried Blood Spot Collection Devices: This study focused on proteomic analysis using dried blood spot samples, a method enabling less invasive sampling with broader clinical applications. The integration of Seer's nanoparticle enrichment improved the number of proteins detected-from approximately 1,000 to up to 3,000 when compared to conventional direct processing methods. The approach demonstrated low variability across subjects and illustrated the applicability of Proteograph XT for large-scale studies involving minimal sample volumes. By combining DBS with nanoparticle enrichment, researchers are enabled to conduct in-depth proteomic analysis from minimal samples, which is key for early biomarker discovery. This approach facilitates a more inclusive and accessible model for proteomic research compared to traditional methods, supporting innovation at both individual and population scales. Xenotransplantation: Capturing Immune Dynamics with Ultra-Deep Longitudinal Profiling for Novel Insights in Transplant Research Title: Ultra-Deep Longitudinal Profiling of Plasma and Serum Proteome Provides Critical Insights into the Interaction of Human Organism and Pig Xenotransplants: In a pioneering study of xenotransplantation performed with collaborators at multiple high-profile research institutions, Seer's Proteograph XT was used to perform ultra-deep profiling of plasma and serum proteomes from recipients of genetically modified pig organs. The integration of Proteograph XT with advanced LC-MS workflows enabled comprehensive identification of both human and pig proteins over a period of 61 days, including over 100,000 peptides. This provided a detailed view of immune system responses, complement system dynamics, and physiological adaptation in real-time. For researchers focused on human health and organ transplantation, this study highlights Seer's platform's ability to support deep longitudinal sampling and comparative proteomics, facilitating the identification of biomarkers and immune responses important to advancing xenotransplantation and immunological research.

07:14 EDT ISS issues recommendation in support of Territorial/Hope Bancorp combination - Territorial Bancorp (TBNK) announced that leading independent proxy advisory firm Institutional Shareholder Services has reissued its report assessing Territorial's proposed merger with Hope Bancorp (HOPE). In its report, ISS recommends that Territorial shareholders vote "FOR" the Company's pending merger with Hope Bancorp at the Special Meeting on November 6, 2024, at 8:30 a.m., Hawai'i Time. The Territorial Board of Directors also unanimously recommends that all Territorial shareholders vote "FOR" the Hope Bancorp agreement.

07:11 EDT PolyPid announces publication in IJS on Phase 3 SHIELD I trial of D-PLEX100 - PolyPid announced a publication in the International Journal of Surgery, IJS, titled, "Effect of Local Prolonged-Release Incisional Doxycycline on Surgical Site Infection Prophylaxis in Abdominal Colorectal Surgery: The SHIELD I Randomized Clinical Trial." Phase 3 SHIELD I trial results: A total of 104 patients experienced a primary outcome event: 45/485 in D-PLEX100 versus 59/489 in SoC. The clinically meaningful 23% event reduction in the D-PLEX100 treatment arm was not statistically significant. In the greater than 20 cm incision length pre-specified subgroup, a statistically significant 54% reduction in primary outcome events was observed in D-PLEX100 compared with SoC. Analysis of the key secondary efficacy outcome, incisional SSI, also indicated a 54.6% reduction in the greater than 20 cm incision subgroup. Exploratory analysis of the additional secondary efficacy outcomes indicated marked differences in favor of D-PLEX100 vs. SoC in the greater than 20 cm incision length subgroup. There were no safety concerns raised by the independent Data Safety Monitoring Board in SHIELD I.

07:09 EDT Largo reports Q3 V2O5 production up 42% y/y to 3,072 tons - Largo reports its strongest quarterly production in seven quarters with 3,072 tonnes or 6.8M lbs of vanadium pentoxide or V2O5 equivalent in Q3. Ilmenite production increased 90% over Q2 to 16,383 tonnes, with sales of 19,572 tonnes, representing a 60% increase over the same prior comparative quarter. While vanadium sales totaled 1,961 tonnes, the Company continues to optimize its global sales strategy, including a reduction of excess vanadium inventories while leveraging the expertise of its seasoned commercial team to unlock emerging opportunities in the vanadium and titanium sectors. The Company is also pleased to announce that it has signed binding documentation with the Commodities business of a New York-based asset manager, with over $20B in assets under management , to supply 2,100 tonnes of standard grade V2O5 for consideration of approximately $23.5M. Largo expects to deliver the material in staggered shipments between October 17 and March 31 with funds being received upon each delivery. At the option of the Buyer, who must elect the total volume no later than 90 calendar days prior to September 30, 2027, Largo is obligated to repurchase up to a maximum of 2,100 tonnes of standard grade V2O5 at a fixed price not exceeding $7.00 per lb V2O5, with delivery required by September 30, 2027...

07:08 EDT PyroGenesis signs $19.6M 3-year contract for hyper-powered 20MW plasma torch - PyroGenesis Canada announces a signed contract valued at approximately US$19.6 million from an existing U.S. client which provides technology and test services geared to solving critical defense, military, aeronautics, and space exploration challenges. The name of the client will remain anonymous for confidentiality reasons. The client, which previously ordered a 4.5MW plasma torch system from PyroGenesis in August 2023, regularly serves as a prime contractor for the U.S. government. This new project does not impact the ongoing 4.5MW plasma torch system project.

07:06 EDT Catalent issues letter to customers regarding acquisition by Novo Holdings - Catalent issued the following open letter to customers: "I want to correct a few key inaccuracies that have been reported in the press regarding Novo Holdings' pending acquisition of Catalent and reiterate that we are, and will continue to be, driven by our mission to develop, manufacture and supply products that help people live better and healthier lives. Novo Holdings is a global life science investment firm that is focused on creating long-term sustainable value. Following the closing of our transaction, as a private company under Novo Holdings' ownership, Catalent will continue to operate as a leading global, independent, full-service CDMO. Catalent's remaining network of nearly 50 global sites will continue to: Provide you the latest technology and capabilities, deep experience, scalable capacity, proven regulatory expertise, and commitment to excellence; Partner closely with you to successfully bring your products through development and clinical trials, and reliably supply your needs for commercial product launch and beyond; Offer fill and finish services for sterile products for large and small molecules, including gene and cell therapies - areas in which we continue to invest and expand; and Work with you to expand patient access to much needed treatments and cures. I am also excited to announce I will continue to lead Catalent as President and CEO following the transaction close. A key factor in my decision to continue in my role is Novo Holdings' commitment to provide support and capital to ensure unparalleled service to our customers and create new jobs as we drive Catalent's growth. I look forward to partnering with all of our employees and Novo Holdings in this next chapter. Since the announcement of this pending acquisition, all of us at Catalent have remained focused on ensuring that a reliable and high-quality supply of products is available for the patients that need them. As a result, Catalent has continued to experience strong levels of new business wins across our offerings, and we are honored by the confidence you place in us and greatly appreciate your loyalty. I want to be clear: our commitments to you will not change, your products will remain our focus and your proprietary information will be protected. Looking forward, our Patient First operating principle will remain central to how we work, engaging our employees and aligning them with your missions. This is our commitment to you and the patients you serve." Catalent's acquisition by Novo Holdings is expected to close towards the end of calendar year 2024, subject to customary closing conditions, including receipt of required regulatory approvals. The transaction is not subject to any financing contingency.

07:06 EDT Avacta,Tempus AI enter collaboration for AI-driven drug development - Avacta Therapeutics (AVCT) announces the initiation of an artificial intelligence-focused collaboration with Tempus AI (TEM). The strategic collaboration will provide Avacta access to Tempus' multimodal datasets comprising primary tumor samples and associated clinical data from over 200,000 patients across a broad range of cancer indications. The collaboration is designed to leverage these data to characterize the deep biology of the tumor microenvironment and fibroblast activation protein activity upon which its pre CISION technology is based. In addition, Avacta has recently expanded its pre CISION platform with the addition of two new preclinical programs: AVA6103 and AVA7100. AVA6103 is a novel pre CISION-enabled peptide drug conjugate comprising exatecan, a potent topoisomerase I inhibitor, designed to deliver its powerful anti-tumor effects directly to the tumor while minimizing exposure to healthy tissues. AVA7100 is a first-in-class Affimer drug conjugate, aimed at cancers with varying levels of FAP expression, including low FAP. Together, these programs reflect the versatility of the pre CISION platform and its potential to address a broad range of cancer indications. Avacta plans to leverage these insights to further enhance its pre CISION platform reach through the identification of the full addressable patient populations for its clinical programs. Tempus's analytical support and computational biology experts will collaborate in the data analysis with the Avacta team.

07:05 EDT Mammoth Energy's Cobra Acquisitions receives $18.4M from PREPA - Cobra Acquisitions, a wholly owned subsidiary of Mammoth Energy Services, announced the receipt of $18.4M from the Puerto Rico Electric Power Authority in accordance with the previously announced Settlement Agreement.

07:03 EDT Cibus announces restructuring including reduction in force - Cibus announced a restructuring and cost reduction initiatives, including a reduction in force, to optimize the Company's business and cost structure in alignment with its strategic priority to advance its nearest-term commercial opportunities. The Company expects these actions, along with other initiatives, to generate cost savings of approximately $10M on an annualized run-rate basis. When these and other initiatives are fully implemented by early 2025, the Company expects them to translate to a reduction in monthly cash use by approximately 20%. These initiatives are a result of the Company's realigned organization focused on its herbicide resistant traits in Rice, continuing development of its Soybean platform and leveraging its family of multi-crop traits that include disease tolerance in Canola and Winter Oilseed Rape. The Company will also continue to opportunistically pursue partner-funded projects. The RIF is expected to result in one-time charges for accrued vacation and severance of approximately $0.35M in the fourth quarter of 2024. Rory Riggs, CEO, stated, "This restructuring is a necessary step for the Company in our continued transformation from an R&D-focused company to thefirst commercial stage gene editing company in agriculture with the support from top-tier global seed companies. Our streamlined organization will allow us to more efficiently focus our efforts on executing on our product launches with our herbicide resistant traits in Rice and traits for pod shatter reduction in Canola, while maintaining the ability to capitalize on our continued positive progress developing our Soybean platform and advancing our traits for Sclerotinia resistance and herbicide tolerance HT2 trait."

07:03 EDT U Power signs Memorandum of Understanding with Ualabee Corp. - U Power announced the signing of a Memorandum of Understanding with Ualabee Corp., a South American mobile travel platform. The strategic partnership aims to integrate U Power's proprietary UOTTA battery-swapping technology into Ualabee's ride-hailing services across South America, marking a significant step in the company's global expansion strategy. The strategic partnership is set to revolutionize South America's ride-hailing industry by integrating U Power's innovative UOTTA battery-swapping system and compatible EVs into Ualabee's operations. This comprehensive collaboration goes beyond technology provision, encompassing the deployment of battery-swapping infrastructure, implementation of digital payment systems, and utilization of data analytics to optimize operations. The partnership will unfold in phases, starting with the introduction of UOTTA technology and EVs in key markets, and potentially progressing to local manufacturing of battery-swapping commercial vehicles. In the first quarter of 2025, U Power will introduce its first UOTTA battery-swapping station in Peru, which will have the capacity to serve 100 vehicles equipped with swappable batteries. Throughout 2025, the Company will build an additional 6-8 battery-swapping stations in Peru, bringing the total capacity to 800-1,000 vehicles. Meanwhile, for each of the next five years, Ualabee intends to replace 5,000 of its fuel-powered vehicles with electric vehicles, with an estimated 30% of these adopting the UOTTA battery swapping model. This phased approach underscores both companies' long-term commitment to sustainable transportation in South America, promising enhanced efficiency and environmental benefits for the region's urban mobility sector.

06:54 EDT Endeavour Silver provides Q3 construction progress update on Terronera - Endeavour Silver provided a Q3 2024 construction progress update for its Terronera Project in Jalisco state, Mexico. The Terronera project made progress during Q3 as the Upper Plant Platform nears completion. Surface mill and infrastructure construction reached 90%, further preparing for advancement into operations. Focus continues on the Lower Platform, where concrete work is well underway, and the Tailing Storage Facility, with underdrain embankment fill and pipe installation advancing at a good pace. Overall project progress - mine development and surface construction - reached 77% completion, with more than $258M of the project's budget spent to date. Project commitments total $270M, 99% of the $271M capital budget. The explosive use permit application was submitted for approval, which is anticipated in Q4 2024. Slashing of an existing portal commenced for access to mine the high-gold grade La Luz vein, which is anticipated to be reached in H1 2025. Mill and surface infrastructure construction was 90% complete and continues to transition to operations. Lower Platform area was nearly 30% complete. The Terronera Project is tracking to begin commissioning systems near the end of Q4.

06:32 EDT Parsons to acquire BCC Engineering for $230M - Parsons has entered into a definitive agreement to acquire BCC Engineering, Florida transportation engineering firm, in an all-cash transaction valued at $230M. BCC, a portfolio company of Trivest Partners, is a full-service engineering firm that provides planning, design, and management services for transportation, civil, and structural engineering projects in Florida, Georgia, Texas, South Carolina, and Puerto Rico. BCC will be integrated into Parsons' North America Infrastructure business unit. Established in Miami, FL, in 1994, BCC is known for its solutions for some of Florida's largest and most complex roadway and bridge projects. The company has delivered over 100 major projects serving every district for the Florida Department of Transportation. The net transaction value of $221M - including $9M of transaction-related tax benefits - represents approximately 13.0x BCC's estimated 2025e EBITDA. For 2025, Parsons expects BCC to generate approximately $110M of gross revenue and be accretive to Parsons' revenue growth and adjusted EBITDA margins. The transaction is expected to close in the next 30 days, subject to customary closing conditions.

06:11 EDT Zymeworks: First patient dosed in Phase 1 trial of ZW171 - Zymeworks announced that the first patient has been dosed in the first-in-human Phase 1 trial to evaluate the safety and tolerability of the investigational therapy ZW171 in the treatment of advanced or metastatic ovarian cancer, NSCLC, and other MSLN-expressing cancers. "We are very pleased to have initiated the clinical evaluation of ZW171 for the treatment of patients with ovarian cancer and NSCLC, where it has the potential to be a highly effective therapy with favorable tolerability based on our preclinical research results," said Jeff Smith, M.D., FRCP, Executive Vice President and Chief Medical Officer at Zymeworks. "Initiation of this trial marks a significant step forward in our effort to bring a potential new treatment to people living with difficult to treat cancers and highlights our goal to advance two therapeutic candidates, ZW171 and ZW191, into clinical studies in 2024."

06:05 EDT Construction Partners to acquire Asphalt Inc. for $654M in cash, 3M shares - Construction Partners announced that it has entered into a definitive agreement to acquire Asphalt Inc. d/b/a Lone Star Paving, headquartered in Austin, Texas. Lone Star is a vertically integrated asphalt manufacturing and paving company operating in markets in central Texas, with 10 hot-mix asphalt plants, four aggregate facilities, and one liquid asphalt terminal supporting its operations. This acquisition will be immediately accretive to earnings upon closing and is anticipated to generate an annualized run-rate contribution of $530M of revenue and $120M of adjusted EBITDA in FY25. Under the terms of the definitive agreement, CPI will acquire all of the outstanding membership units of Lone Star for $654M in cash and 3M shares of CPI's Class A common stock. In addition, CPI will pay cash to the sellers of Lone Star in an amount equal to the working capital remaining in Lone Star at the closing in four quarterly installments following the closing and purchase from the sellers of Lone Star, upon receipt of specified governmental entitlements, an entity holding certain real property for $30M in cash. CPI expects to finance the cash portion of the purchase price with the proceeds of debt financing. The transaction is expected to close in the first quarter of CPI's 2025 fiscal year, subject to certain regulatory approvals and the satisfaction of other customary closing conditions.

06:00 EDT Atlantic Union Bankshares to acquire Sandy Spring Bancorp for $1.6B

05:30 EDT Nokia, VNPT announce new partnership to deploy 5G technology in Vietnam - Nokia and Vietnam Posts and Telecommunications Group, or VNPT, one of Vietnam's telecommunications operators, announced a new partnership to deploy 5G technology. This development marks a new milestone in the long-standing collaboration between the two companies, reinforcing their commitment to providing a digital infrastructure in Vietnam. Nokia is also manufacturing its 5G products locally in Vietnam highlighting its commitment to the region. As part of this agreement, Nokia will deploy equipment from its 5G AirScale portfolio, powered by its energy-efficient ReefShark System-on-Chip technology. These provide premium connectivity, low latency, enhanced network capacity, and reduced power consumption. Nokia will also deploy its AI-based 5G MantaRay network management solution which will greatly improve VNPT's network operation efficiency.

05:20 EDT Ionis Pharmaceuticals announces CHMP recommends approval for Wainzua - Ionis Pharmaceuticals (IONS) announced that Ionis' and AstraZeneca's (AZN) Wainzua has been recommended for approval by the Committee for Medicinal Products for Human Use, or CHMP, in the European Union, or EU, for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, commonly referred to as hATTR-PN or ATTRv-PN. If approved by the European Commission, Wainzua will be the only approved medicine in the EU for the treatment of ATTRv-PN that can be self-administered monthly via an auto-injector.

05:10 EDT Elixirr International acquires Hypothesis, terms undisclosed - Elixirr announces the acquisition of Hypothesis, the US-based disruptive insights and strategy firm. The Group has already worked closely alongside Hypothesis on a client engagement prior to the acquisition. Through this acquisition, Hypothesis' CEO, Maria Vallis, will now join Elixirr as partner, based out of Los Angeles, California. Hypothesis was founded in 2000 by Maria Stark and Jeff Seltzer.